POMDOCTOR LIMITED (POM) restores Nasdaq $1.00 bid price compliance
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
POMDOCTOR LIMITED, a digital healthcare company listed on Nasdaq under the symbol POM, reports that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). Nasdaq notified the company on July 10, 2026 that the matter is closed after its American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for 10 consecutive business days from June 25 to July 9, 2026.
The company had previously received a Nasdaq notice on January 29, 2026 after its ADS closing bid price stayed below $1.00 for 30 consecutive business days. With compliance restored, POMDOCTOR’s ADSs will continue to be listed on Nasdaq, and the company continues to focus on AI-enabled and predictive healthcare solutions.
Positive
- None.
Negative
- None.
Key Figures
Minimum bid price requirement: $1.00 per share
Non-compliance period length: 30 consecutive business days
Compliance period length: 10 consecutive business days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5450(a)(1) minimum bid price threshold
Non-compliance period length
30 consecutive business days
ADS closing bid price below $1.00 before January 29, 2026 notice
Compliance period length
10 consecutive business days
ADS closing bid price at or above $1.00 from June 25 to July 9, 2026
Compliance letter date
July 10, 2026
Date Nasdaq informed company that bid price compliance was regained
Initial Nasdaq notice date
January 29, 2026
Date Nasdaq notified company of bid price deficiency
Key Terms
Nasdaq Listing Rule 5450(a)(1), minimum bid price requirement, American Depositary Shares, forward-looking statements, +1 more
5 terms
Nasdaq Listing Rule 5450(a)(1) regulatory
"compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1)"
Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.
minimum bid price requirement regulatory
"regained compliance with the minimum bid price requirement of $1.00 per share"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
forward-looking statements regulatory
"Certain statements in this announcement are forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
predictive healthcare capabilities medical
"focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities"
FAQ
What did POM (POMDOCTOR LIMITED) announce regarding its Nasdaq listing?
POMDOCTOR LIMITED announced it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1), and its American Depositary Shares will continue to be listed on Nasdaq.
What is the Nasdaq minimum bid price requirement mentioned by POM (POMDOCTOR LIMITED)?
Nasdaq Listing Rule 5450(a)(1) requires a minimum bid price of $1.00 per share. POMDOCTOR LIMITED’s American Depositary Shares met or exceeded this price for 10 consecutive business days, restoring compliance with the rule.
When did POM (POMDOCTOR LIMITED) receive confirmation it was back in compliance with Nasdaq rules?
POMDOCTOR LIMITED received a Compliance Letter on July 10, 2026 from Nasdaq. The letter confirmed the company had regained compliance with the $1.00 minimum bid price requirement, and that the compliance matter had been closed.
What led to Nasdaq’s earlier notice to POM (POMDOCTOR LIMITED) about bid price issues?
On January 29, 2026, POMDOCTOR LIMITED received a Nasdaq notification because the closing bid price of its American Depositary Shares had been below $1.00 per share for 30 consecutive business days, triggering a compliance review process.
Over which period did POM (POMDOCTOR LIMITED) maintain the required bid price to regain compliance?
Nasdaq determined that from June 25, 2026 to July 9, 2026, the closing bid price of POMDOCTOR LIMITED’s American Depositary Shares was $1.00 per share or greater for 10 consecutive business days, satisfying the bid price requirement.
What business focus does POM (POMDOCTOR LIMITED) highlight in this disclosure?
POMDOCTOR LIMITED describes itself as a digital healthcare company focused on AI-enabled healthcare solutions and expanding predictive healthcare capabilities, leveraging physician resources, wearable technologies, artificial intelligence and real-world healthcare data.